Peter Attia

Because you need a win.

Yeah.

You got to demonstrate a win.

Should the first one be pancreatic adeno?

You have far more patients...

Life expectancy is a little bit longer, but it's equally fatal, meaning metastatic or advanced pancreatic cancer is uniformly fatal.

Should we be using that as a model where, of course, look, all cancers are heterogeneous, but it might be that GBM is even more so.

And it's also heavily impacted by the radiation.

The radiation then completely changes it.

Virtually all of these patients are going to need radiation, which

makes it even more difficult.

So anyway, look, I don't want to offer advice from the peanut gallery because I'm in the peanut gallery for a reason on this, but that might be something worth considering.

Let's talk about Alzheimer's disease.

equally devastating, much longer tail, but in my mind seems somewhat easier to address through metabolic therapies because at least in the subset of those patients for whom an energetic crisis is at the core, and I don't think that that's all cases, I think that's also a very heterogeneous disease, but at least one subset of these people are probably in an energetic crisis.

What do we know about the current research and what's the current state of affairs for using ketogenic therapies?

If you have two copies.

There are a handful of genes in which you are destined to get it.

Unfortunately, at this point, PSCN1, PSCN2, APP.

But again, I mean, 25% of the population are heterozygous for APOE4.

Their risk is twofold higher.